Understanding payment in clinical trials

Many people wonder whether clinical trials offer financial compensation for participation, as these trials can require a significant time investment and involve some inconvenience. While clinical trials are essential for advancing medical knowledge by testing new treatments, they often offer compensation to encourage participation. However, before committing, it is important to know how payment works, what costs are covered, and what to expect.

The compensation offered in clinical trials varies depending on several factors, including the type of trial, the level of involvement, and the institution conducting the research. Some trials provide higher payments for increased risks or longer time commitments, while others may not offer direct compensation but instead cover related expenses such as travel and accommodation.

For example, at FluCamp, payments are based on the duration of the trial, including residential stays and follow-up visits. Participants can earn up to £4,400 for taking part in clinical trials. It’s important to note that, depending on the amount earned and your financial situation, you may need to report your earnings to HM Revenue and Customs (HMRC). Tax guidelines on this income can be found in the HMRC Employment Income Manual (EIM71105), and it’s advisable to contact HMRC for further advice.

In the UK, the amount you can earn varies significantly. For short-term, early-phase drug trials, compensation can range from £1,000 to £4,000 for a commitment that lasts from a few days to a week. Long-term studies, which require regular visits over a longer period, typically offer lower payments per visit, but these can add up to substantial amounts. For example, you may receive £200 to £500 per visit for a study that spans months or years.

Payment for clinical trials is usually made in one lump sum at the end of the study, though some trials may offer staggered payments throughout the course of your involvement. For example, at FluCamp, compensation is given after each screening visit, with additional payments made after the residential stay and the final follow-up visit.

Many trials also cover certain expenses, such as travel, accommodation, or meals, especially if multiple clinic visits are required. At FluCamp, participants receive reimbursement for travel expenses, including £40 for attending the initial pre-screening appointment. This helps ease some of the financial burdens associated with participation.

While it’s possible to take part in multiple clinical trials, there are regulations in place to ensure your safety. The Medicines and Healthcare products Regulatory Agency (MHRA) provides guidelines that govern participation in trials, and you must disclose any ongoing involvement in other studies. This ensures the integrity of the research and protects your health.

Participating in clinical trials offers the opportunity to contribute to medical research while potentially receiving compensation for your time and effort. However, payment structures can vary widely, so it’s important to understand the details of any trial you are considering before committing.

Clinical trials can provide financial compensation for your involvement, but the specifics depend on the trial and the level of commitment required.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring